Auxilium Pharmaceuticals Inc.’s drug Xiaflex (collagenase clostridium histolyticum) may be its more closely-watched product offering, but the injectable is still failing to drive significant revenues to the company’s top line. Instead, a lesser known testosterone gel has been providing the company with significant sales growth, as well as the opportunity to partner with Big Pharma.
The Malvern, Pa.-based company reported second quarter results on July 30, marking the first profitable quarter in its history. The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?